(Total Views: 398)
Posted On: 07/13/2025 4:11:51 AM
Post# of 155150
From Google:
In summary, CytoDyn's leronlimab targets CCR5 receptors on the surface of CD4+ T cells, including resting CD4+ T cells.
This binding may inhibit HIV entry and potentially stabilize CCR5 expression on these cells, thereby potentially impacting the course of HIV infection and the latent reservoir.
__
Ahhh, although the resting CD4+ T cells are not giving off particles --- aka: "cold"....
LL binds to their CCR5.
Explaining the increase mentioned on pg. 10
Until this, did not personally know/read about resting infected CD4 & resevoir
Similar to mTNBC, if validated higher dosed LL upregulated the resting CD4 resevoir....
Huge...
In summary, CytoDyn's leronlimab targets CCR5 receptors on the surface of CD4+ T cells, including resting CD4+ T cells.
This binding may inhibit HIV entry and potentially stabilize CCR5 expression on these cells, thereby potentially impacting the course of HIV infection and the latent reservoir.
__
Ahhh, although the resting CD4+ T cells are not giving off particles --- aka: "cold"....
LL binds to their CCR5.
Explaining the increase mentioned on pg. 10
Until this, did not personally know/read about resting infected CD4 & resevoir
Similar to mTNBC, if validated higher dosed LL upregulated the resting CD4 resevoir....
Huge...
(6)
(0)
